Plasma Aβ42 as Biomarker of Prodromal Alzheimer&#039;s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study

Albani, Diego; Marizzoni, Moira; Ferrari, Clarissa; Fusco, Federica; Boeri, Lucia; Raimondi, Ilaria; Jovicich, Jorge; Babiloni, Claudio; Soricelli, Andrea; Lizio, Roberta; Galluzzi, Samantha; Cavaliere, Libera; Didic, Mira; Schönknecht, Peter; Molinuevo, José Luis; Nobili, Flavio; Parnetti, Lucilla; Payoux, Pierre; Bocchio, Luisella; Salvatore, Marco; Rossini, Paolo Maria; Tsolaki, Magda; Visser, Pieter Jelle; Richardson, Jill C; Wiltfang, Jens; Bordet, Régis; Blin, Olivier; Forloni, Gianluigi; Frisoni, Giovanni

doi:10.3233/JAD-180321

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Plasma Aβ42 as Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study
Authors		Albani, Diego Marizzoni, Moira Ferrari, Clarissa Fusco, Federica Boeri, Lucia Raimondi, Ilaria Jovicich, Jorge Babiloni, Claudio Soricelli, Andrea Lizio, Roberta Galluzzi, Samantha Cavaliere, Libera Didic, Mira Schönknecht, Peter Molinuevo, José Luis Nobili, Flavio Parnetti, Lucilla Payoux, Pierre Bocchio, Luisella Salvatore, Marco Rossini, Paolo Maria Tsolaki, Magda Visser, Pieter Jelle Richardson, Jill C Wiltfang, Jens Bordet, Régis Blin, Olivier Forloni, Gianluigi Frisoni, Giovanni show all authors [1 - 29]
Published in		Journal of Alzheimer's disease. 2018
Abstract		It is an open issue whether blood biomarkers serve to diagnose Alzheimer's disease (AD) or monitor its progression over time from prodromal stages. Here, we addressed this question starting from data of the European FP7 IMI-PharmaCog/E-ADNI longitudinal study in amnesic mild cognitive impairment (aMCI) patients including biological, clinical, neuropsychological (e.g., ADAS-Cog13), neuroimaging, and electroencephalographic measures. PharmaCog/E-ADNI patients were classified as "positive" (i.e., "prodromal AD" n = 76) or "negative" (n = 52) based on a diagnostic cut-off of Aβ42/P-tau in cerebrospinal fluid as well as APOE ε 4 genotype. Blood was sampled at baseline and at two follow-ups (12 and 18 months), when plasma amyloid peptide 42 and 40 (Aβ42, Aβ40) and apolipoprotein J (clusterin, CLU) were assessed. Linear Mixed Models found no significant differences in plasma molecules between the "positive" (i.e., prodromal AD) and "negative" groups at baseline. In contrast, plasma Aβ42 showed a greater reduction over time in the prodromal AD than the "negative" aMCI group (p = 0.048), while CLU and Aβ40 increased, but similarly in the two groups. Furthermore, plasma Aβ42 correlated with the ADAS-Cog13 score both in aMCI patients as a whole and the prodromal AD group alone. Finally, CLU correlated with the ADAS-Cog13 only in the whole aMCI group, and no association with ADAS-Cog13 was found for Aβ40. In conclusion, plasma Aβ42 showed disease progression-related features in aMCI patients with prodromal AD.
Keywords		Amnesic mild cognitive impairment — Amyloid-beta peptide — Biomarkers — Clinical trial — Clusterin — PharmaCog 62 project — Prodromal Alzheimer's disease
Identifiers		DOI: 10.3233/JAD-180321 PMID: 30149449
Full text		Article (Published version) (350 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de réadaptation et gériatrie
Research group		Troubles de mémoire et maladie d'Alzeimer (935)
Citation (ISO format)		ALBANI, Diego et al. Plasma Aβ42 as Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. In: Journal of Alzheimer's Disease, 2018. doi: 10.3233/JAD-180321 https://archive-ouverte.unige.ch/unige:116118